Follow-up Schedule and Monitoring for Pediatric Nephrotic Syndrome After Remission
Children with nephrotic syndrome in remission require close, structured monitoring with urine protein checks at home during infections and regular clinic visits every 3-6 months, with the specific frequency determined by their disease pattern (frequently relapsing, steroid-dependent, or infrequent relapses).
Home Monitoring Requirements
Daily urine dipstick monitoring during any infection or illness is essential, as upper respiratory tract infections commonly trigger relapses in children with frequently relapsing or steroid-dependent nephrotic syndrome 1.
Parents should be trained to perform and document urine protein measurements at home, though lack of insurance coverage for urine dipsticks in the United States represents a significant barrier to optimal disease management 2.
First morning urine samples provide the most reliable assessment for detecting early relapse, defined as proteinuria ≥3+ on dipstick or urine protein-to-creatinine ratio >2 mg/mg for 3 consecutive days 3.
Clinic Visit Schedule Based on Disease Pattern
For Children with Infrequent Relapses
- Clinic visits every 6 months are appropriate once stable remission is established 3.
- Each visit should include blood pressure measurement, growth parameters (height and weight), and assessment for steroid-related complications 3.
For Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome
- More frequent monitoring every 3 months is warranted given higher relapse risk 3.
- Children on glucocorticoid-sparing agents (calcineurin inhibitors, rituximab, cyclophosphamide, levamisole, or mycophenolate mofetil) require additional drug-specific monitoring 1.
Laboratory Monitoring Parameters
Routine Assessments at Each Visit
- Serum creatinine and estimated glomerular filtration rate to detect progression to chronic kidney disease, particularly important as 2% of children with frequently relapsing nephrotic syndrome may develop CKD 4.
- Serum albumin and lipid panel when clinically indicated, especially if proteinuria recurs 3.
- Urinalysis with microscopy to assess for hematuria or other concerning findings 3.
Medication-Specific Monitoring
For calcineurin inhibitors (tacrolimus/cyclosporine):
- Drug trough levels every 2-4 weeks initially, then every 3 months once stable 3.
- Serum creatinine monitoring for nephrotoxicity risk, as tacrolimus use as first steroid-sparing medication predicts higher nephrotoxicity rates 5.
- Blood pressure at every visit, as hypertension is a common adverse effect 3.
For cyclophosphamide:
- Complete blood count every 2 weeks during treatment to monitor for leukopenia 3.
- Urinalysis for hematuria (hemorrhagic cystitis surveillance) 3.
For rituximab:
- B-cell counts (CD19/CD20) at 3-6 month intervals to guide re-dosing decisions 3.
- Immunoglobulin levels every 6 months to detect hypogammaglobulinemia 3.
Assessment of Remission Status and Relapse Risk
The critical window for relapse surveillance is 3 years, as 98% of relapses occur within 3 years of initial diagnosis or the last relapse event 4.
Children meeting International Pediatric Nephrology Association criteria for frequently relapsing nephrotic syndrome (≥2 relapses within 6 months of initial response or ≥4 relapses in any 12-month period) have similar relapse rates and CKD risk as those meeting KDIGO 2021 criteria, supporting use of IPNA definitions 4.
Prolonged remission after cyclophosphamide occurs in only 28.6% of children, and after tacrolimus in 14.2%, meaning most require ongoing surveillance and potential additional immunosuppression 5.
Monitoring for Glucocorticoid Toxicity
Growth velocity assessment at every visit using standardized growth charts, as impaired statural growth indicates need for glucocorticoid-sparing strategies 1.
Ophthalmologic examination annually for cataract screening in children on prolonged or repeated glucocorticoid courses 3.
Bone density assessment should be considered in children with cumulative prednisone exposure >12 months 3.
Blood pressure and glucose monitoring at each visit to detect hypertension and hyperglycemia 3.
Transition Planning
Begin transition discussions by age 12-14 years for eventual transfer to adult nephrology care 3.
Ensure adolescents understand their disease pattern, medication regimen, and importance of continued monitoring before transfer 3.
Common Pitfalls to Avoid
Do not routinely give daily glucocorticoids during upper respiratory tract infections to prevent relapses in children with frequently relapsing or steroid-dependent nephrotic syndrome, as the PREDNOS2 study demonstrated no benefit of fixed-dose prednisolone versus placebo 1.
Avoid delaying genetic testing in children with steroid-resistant features, as 10-30% have identifiable podocyte gene mutations that alter management 6.
Do not assume treatment resistance based solely on steroid response—73% of children with steroid-resistant nephrotic syndrome achieve complete remission with other immunosuppression and have good kidney outcomes comparable to steroid-sensitive patients 4.